This Review summarizes the results from preclinical and clinical studies that use CD3-specific monoclonal antibody therapy and highlights future combination opportunities to enhance the efficacy of ...
Multiple Myeloma (MM) is the second most common hematological malignancy that originates from plasma cells. Over the last 20 years, treatment for patients of MM has advanced significantly; but despite ...
Figure 1: CD3-specific antibody treatment increases systemic TGF-β, which requires the presence of macrophages and iDCs. Figure 2: iDCs produce TGF-β upon ingestion of apoptotic cells and induce Foxp3 ...
Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...
ROYERSFORD, Pa.--(BUSINESS WIRE)--Abzyme Therapeutics LLC, a biotech company focused on developing antibodies for diagnostic and therapeutic applications, has filed a patent application entitled ...
Avelumab (MSB0010718C; anti-PD-L1) in combination with other cancer immunotherapies in patients with advanced malignancies: The phase 1b/2 JAVELIN Medley study. Background: MGD009 is a B7-H3 x CD3 ...
CD3 (including its subunits CD3ε, CD3δ, CD3γ, and CD3ζ) is the central component of the TCR-CD3 complex and is crucial for recognizing T cells and responding to antigens. Every subunit of CD3 has ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the American Association for Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback